胶质瘤治疗市场－全球产业规模、份额、趋势、机会、预测：按疾病、治疗类型、分级、最终用户、地区和竞争格局划分，2021-2031年

全球胶质母细胞瘤治疗市场预计将从 2025 年的 93.4 亿美元成长到 2031 年的 147.8 亿美元，复合年增长率为 7.95%。

此领域涵盖针对神经胶质细胞来源的原发性脑肿瘤的治疗性介入，包括手术切除、放射线治疗、化疗和标靶免疫疗法等策略。市场成长趋势的主要驱动因素是全球人口老化，老年人罹患中枢神经系统恶性肿瘤的风险较高，以及此类疾病整体盛行率的上升。此外，医疗基础设施的进步和先进的诊断成像治疗方法。

根据美国中枢神经系统肿瘤登记处的数据，到2024年，胶质瘤将占所有原发性脑肿瘤和其他中枢神经系统肿瘤的约22.9%。儘管疾病负担如此沉重，但市场仍面临一个重大障碍：血脑障壁。血脑屏障严重限制了治疗药物向肿瘤部位的输送。这一生理屏障阻碍了有效全身治疗方法的研发，常常导致临床试验的高失败率，阻碍了市场的快速扩张。

市场驱动因素

强大的临床研发管线，包括新型免疫疗法和生物目标，正成为市场扩张的重要催化剂，製药公司也日益重视IDH变异抑制剂以应对抗药性机制。能够延缓疾病进展的标靶治疗获得监管批准是一项重大进展。例如，2024年8月，施维雅宣布FDA核准VORANIGO上市。在INDIGO III期临床试验中，与安慰剂相比，borasidenib可使2级IDH突变型胶质母细胞瘤患者的肿瘤进展或死亡风险降低61%。这些临床里程碑证明了精准医疗的有效性，并刺激了对该治疗领域的进一步投资。

同时，非侵入性治疗方法，特别是肿瘤电场疗法（TTF）的技术创新，正在透过提高存活率来改变治疗模式。研发人员正在将这些治疗方法与标准放射线治疗结合，以增强局部控制。根据Novocure公司于2024年5月发表的METIS III期临床试验结果，接受肿瘤电场疗法治疗的患者颅内进展的中位数时间为21.9个月，显着长于对照组的11.3个月。鑑于这些恶性肿瘤的高死亡率，这些进展至关重要。美国癌症协会估计，2024年美国将有约18,760人死于脑部和其他神经系统肿瘤，凸显了发展新型治疗方法的必要性。

市场挑战

血脑障壁是全球胶质母细胞瘤治疗市场面临的一大障碍，因为它从物理层面阻止了治疗药物到达肿瘤部位。这种生理防御机制阻碍了大多数全身性药物的通过，使药物製剂的研发变得复杂，并需要耗费巨资进行研发。因此，开发平臺充满障碍，延缓了进展，并增加了新治疗方法上市的成本。

这一障碍导致临床试验中较高的脱落率，直接阻碍了市场成长。由于药物输送不足，疗效难以证实，限制了商业化机会，并阻碍了持续投资。根据美国脑肿瘤学会统计，截至2024年，仅有四种药物获得FDA核准用于治疗胶质母细胞瘤。可上市产品的匮乏限制了行业相关人员的产生收入机会，并凸显了血脑障壁如何透过阻碍新治疗方法的商业化，有效地抑制了该领域的扩张。

市场趋势

嵌合体抗原受体（CAR）T细胞疗法的进展正在从根本上改变固态肿瘤异质性的挑战。研究人员目前正在设计能够同时针对多种抗原（例如EGFRvIII和野生型EGFR）的T细胞，以期阻止过去导致治疗失败的抗原逃脱机制。这种从单靶点到多标靶细胞工程的转变，正为復发患者带来前所未有的疗效。例如，2024年3月，麻省总医院报告称，接受新型CAR-TEAM细胞治疗的患者疗效迅速，其中一名患者在治疗69天后肿瘤面积缩小了60.7%。这显示细胞疗法正逐渐成为治疗方法中枢神经系统恶性肿瘤的有效方法。

同时，能够穿过血脑障壁的新型药物递送系统的研发正在克服该领域最顽固的生理障碍。为了提高全身性细胞毒性药物的疗效，研发人员正在检验植入式超音波技术。这项技术能够暂时破坏血脑障壁，使化疗药物达到治疗浓度，进而到达脑实质。这种方法使得一些先前因颅内渗透性差而受限的药物得以有效再利用。根据Carsela公司于2024年3月公布的SonoCloud-9 I/II期临床试验的积极结果，接受Carboplatin联合该设备治疗的复发性胶质母细胞瘤患者的一年生存率达到了58%。与传统对照组相比，这是一个显着的进步，也标誌着器械与药物联合治疗策略取得了进展。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球胶质瘤治疗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 疾病特异性资讯（星状细胞瘤、少突星状细胞瘤、少突胶质细胞瘤）
  • 治疗方法（手术、化疗、放射线治疗、其他）
  • 依分化程度（分化不良、分化良好）
  • 依最终使用者（医院/诊所、门诊手术中心、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美胶质瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲胶质瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区胶质瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲胶质瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲胶质瘤治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章 全球胶质瘤治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• F. Hoffmann-La Roche Ltd
• Arbor Pharmaceuticals LLC
• Merck & Co. KGaA
• Sun Pharmaceutical Industries Ltd
• Amgen Inc
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc
• Amneal Pharmaceuticals Inc
• Karyopharm Therapeutics Inc
• Biocon Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Glioma Treatment Market is projected to expand from a valuation of USD 9.34 Billion in 2025 to USD 14.78 Billion by 2031, reflecting a CAGR of 7.95%. This sector encompasses therapeutic interventions for primary brain tumors derived from glial cells, employing strategies such as surgical resection, radiation therapy, chemotherapy, and targeted immunotherapies. The market's upward trajectory is fundamentally fueled by an aging global population that exhibits higher susceptibility to central nervous system malignancies, alongside a general increase in the prevalence of these conditions. Additionally, advancements in healthcare infrastructure and superior diagnostic imaging technologies are enabling earlier detection, thereby driving the demand for both standard and innovative therapeutic regimens.

According to data from the Central Brain Tumor Registry of the United States, gliomas represented approximately 22.9% of all primary brain and other central nervous system tumors in 2024. Despite this significant disease burden, the market encounters a major impediment in the form of the blood-brain barrier, which severely limits the delivery of therapeutic agents to the tumor site. This physiological obstacle hampers the development of effective systemic treatments and frequently results in high failure rates during clinical trials, consequently preventing rapid market expansion.

Market Driver

A robust clinical pipeline featuring novel immunotherapies and targeted biologics serves as a primary catalyst for market expansion, with pharmaceutical companies increasingly prioritizing IDH-mutant inhibitors to address resistance mechanisms. A pivotal development involves the regulatory success of targeted therapies capable of delaying disease progression. For instance, Servier announced in August 2024 via their 'FDA Approves VORANIGO' release that the Phase 3 INDIGO clinical trial showed vorasidenib reduced the risk of tumor progression or death by 61% in patients with Grade 2 IDH-mutant glioma compared to a placebo. Such clinical milestones validate the efficacy of precision medicine and encourage further investment into expanding the therapeutic landscape.

Simultaneously, technological innovations in non-invasive modalities, specifically Tumor Treating Fields, are altering treatment paradigms by extending survival rates. Developers are integrating these fields with standard radiotherapy to enhance local control. As reported by Novocure in May 2024 regarding the 'METIS Phase 3 Clinical Trial,' patients treated with Tumor Treating Fields therapy demonstrated a median time to intracranial progression of 21.9 months, significantly outperforming the 11.3 months observed in the control arm. These advancements are critical given the high mortality rates associated with these malignancies; the American Cancer Society estimated that in 2024, approximately 18,760 individuals in the United States would die from brain and other nervous system tumors, underscoring the need for these evolving interventions.

Market Challenge

The blood-brain barrier acts as a severe restriction on the Global Glioma Treatment Market by physically blocking therapeutic agents from reaching the tumor site. This physiological defense mechanism prevents the passage of most systemic drugs, complicating drug formulation and necessitating expensive research efforts. Consequently, the development pipeline is fraught with obstacles that delay progress and inflate the cost of bringing new therapies to market.

This impediment directly stunts market growth by contributing to high attrition rates in clinical trials. The inability to demonstrate efficacy due to poor drug delivery results in a sparse commercial landscape, discouraging sustained financial investment. According to the National Brain Tumor Society, in 2024, there were only four FDA-approved drugs available for the treatment of glioblastoma. This low number of marketable products limits revenue generation opportunities for industry players and highlights how the blood-brain barrier effectively bottlenecks the expansion of the sector by preventing the successful commercialization of novel treatments.

Market Trends

The advancement of Chimeric Antigen Receptor (CAR) T-Cell Therapies is fundamentally reshaping the clinical landscape by addressing the challenge of solid tumor heterogeneity in glioblastoma. Researchers are now engineering T-cells capable of targeting multiple antigens simultaneously, such as EGFRvIII and wild-type EGFR, to prevent the antigen escape mechanisms that historically caused treatment failure. This shift from single-target to multi-target cellular engineering is yielding unprecedented responses in patients with recurrent disease; for example, Massachusetts General Hospital reported in March 2024 that patients treated with novel CAR-TEAM cells exhibited rapid responses, with one participant demonstrating a 60.7% decrease in tumor cross-sectional area by day 69, indicating that cellular therapies are becoming a viable modality for central nervous system malignancies.

Simultaneously, the development of novel delivery systems to cross the blood-brain barrier is overcoming the sector's most persistent physiological impediment. To enhance the efficacy of systemic cytotoxic agents, developers are validating implantable ultrasound technologies that temporarily disrupt the blood-brain barrier, allowing therapeutic concentrations of chemotherapy to reach the brain parenchyma. This approach effectively repurposes existing drugs that were previously limited by poor intracranial penetration. According to Carthera's March 2024 announcement regarding positive results from the Phase I/II clinical trial of SonoCloud-9, patients with recurrent glioblastoma who received carboplatin in combination with the device achieved a one-year overall survival rate of 58%, a substantial improvement over historical controls, signifying a move toward device-drug combination strategies.

Key Market Players

• F. Hoffmann-La Roche Ltd
• Arbor Pharmaceuticals LLC
• Merck & Co. KGaA
• Sun Pharmaceutical Industries Ltd
• Amgen Inc
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc
• Amneal Pharmaceuticals Inc
• Karyopharm Therapeutics Inc
• Biocon Ltd

Report Scope

In this report, the Global Glioma Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Glioma Treatment Market, By Disease

• Astrocytoma
• Oligoastrocytoma
• Oligodendroglioma

Glioma Treatment Market, By Treatment Type

• Surgery
• Chemotherapy
• Radiation Therapy
• Others

Glioma Treatment Market, By Grade

• Low Grade
• High Grade

Glioma Treatment Market, By End user

• Hospital & Clinics
• Ambulatory Surgical Centers
• Others

Glioma Treatment Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Glioma Treatment Market.

Available Customizations:

Global Glioma Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Glioma Treatment Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease (Astrocytoma, Oligoastrocytoma, Oligodendroglioma)
  • 5.2.2. By Treatment Type (Surgery, Chemotherapy, Radiation Therapy, Others)
  • 5.2.3. By Grade (Low Grade, High Grade)
  • 5.2.4. By End user (Hospital & Clinics, Ambulatory Surgical Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Glioma Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease
  • 6.2.2. By Treatment Type
  • 6.2.3. By Grade
  • 6.2.4. By End user
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Glioma Treatment Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Grade
      • 6.3.1.2.4. By End user
  • 6.3.2. Canada Glioma Treatment Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Grade
      • 6.3.2.2.4. By End user
  • 6.3.3. Mexico Glioma Treatment Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Grade
      • 6.3.3.2.4. By End user

7. Europe Glioma Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease
  • 7.2.2. By Treatment Type
  • 7.2.3. By Grade
  • 7.2.4. By End user
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Glioma Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Grade
      • 7.3.1.2.4. By End user
  • 7.3.2. France Glioma Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Grade
      • 7.3.2.2.4. By End user
  • 7.3.3. United Kingdom Glioma Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Grade
      • 7.3.3.2.4. By End user
  • 7.3.4. Italy Glioma Treatment Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By Grade
      • 7.3.4.2.4. By End user
  • 7.3.5. Spain Glioma Treatment Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By Grade
      • 7.3.5.2.4. By End user

8. Asia Pacific Glioma Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease
  • 8.2.2. By Treatment Type
  • 8.2.3. By Grade
  • 8.2.4. By End user
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Glioma Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Grade
      • 8.3.1.2.4. By End user
  • 8.3.2. India Glioma Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Grade
      • 8.3.2.2.4. By End user
  • 8.3.3. Japan Glioma Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Grade
      • 8.3.3.2.4. By End user
  • 8.3.4. South Korea Glioma Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By Grade
      • 8.3.4.2.4. By End user
  • 8.3.5. Australia Glioma Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By Grade
      • 8.3.5.2.4. By End user

9. Middle East & Africa Glioma Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease
  • 9.2.2. By Treatment Type
  • 9.2.3. By Grade
  • 9.2.4. By End user
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Glioma Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Grade
      • 9.3.1.2.4. By End user
  • 9.3.2. UAE Glioma Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Grade
      • 9.3.2.2.4. By End user
  • 9.3.3. South Africa Glioma Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Grade
      • 9.3.3.2.4. By End user

10. South America Glioma Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease
  • 10.2.2. By Treatment Type
  • 10.2.3. By Grade
  • 10.2.4. By End user
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Glioma Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By Grade
      • 10.3.1.2.4. By End user
  • 10.3.2. Colombia Glioma Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By Grade
      • 10.3.2.2.4. By End user
  • 10.3.3. Argentina Glioma Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By Grade
      • 10.3.3.2.4. By End user

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Glioma Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. F. Hoffmann-La Roche Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Arbor Pharmaceuticals LLC
• 15.3. Merck & Co. KGaA
• 15.4. Sun Pharmaceutical Industries Ltd
• 15.5. Amgen Inc
• 15.6. Teva Pharmaceutical Industries Ltd
• 15.7. Pfizer Inc
• 15.8. Amneal Pharmaceuticals Inc
• 15.9. Karyopharm Therapeutics Inc
• 15.10. Biocon Ltd

16. Strategic Recommendations

17. About Us & Disclaimer